$0.90
▼ -1.0% Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
Overview
52-week range
$0.95
$1.95
0% of range
Avg surprise (last 3)
-15.6%
Avg reaction (last 2)
+5.4%
100% positive
Latest IV / EM
1894%
EM ±433.3% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Fri May 8, 2026 | Mar/2026 | $-0.18 | $-0.22 | +18.2% | +64.7% | +7.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.16 | — | — | — | — | financials |
| Fri Aug 8, 2025 | Jun/2025 | $-0.22 | $-0.32 | +31.2% | — | — | earnings |
| Fri May 9, 2025 | Mar/2025 | $-0.51 | $-0.26 | -96.2% | — | +3.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.37 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.38 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.31 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.49 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.58 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Fri Aug 14, 2026 | Jun/2026 | OTHER | -$0.20 | -$0.22 | +9.1% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $90,000 | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-6M | — | $-6M | $-8M | $-17M | — | $-13M | $-12M |
| Net income | $-6M | — | $-5M | $-7M | $-16M | — | $-12M | $-11M |
| EPS (diluted) | $-0.18 | — | $-0.16 | $-0.22 | $-0.51 | — | $-0.37 | $-0.38 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $42M | $48M | $53M | $60M | $65M | $73M | $79M | $86M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $43M | $49M | $54M | $61M | $66M | $75M | $80M | $87M |
| Total assets | $45M | $52M | $56M | $63M | $69M | $77M | $82M | $90M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $43M | $44M | $42M | $44M | $43M | $44M | $44M | $46M |
| Total equity | $2M | $8M | $14M | $19M | $26M | $33M | $38M | $44M |